Prematür ejakülasyona güncel yaklaşım
Yıl: 2023 Cilt: 25 Sayı: 2 Sayfa Aralığı: 103 - 111 Metin Dili: Türkçe DOI: 10.24898/tandro.2023.13334 İndeks Tarihi: 06-07-2023
Prematür ejakülasyona güncel yaklaşım
Öz: Prematür ejakülasyon (PE), tüm yaş gruplarını etkileyen en yaygın gö - rülen ejakülasyon bozukluğudur. Hastada psikolojik strese ve özgüven kaybına yol açan, yaşam kalitesi üzerinde negatif etkisi olan klinik bir durumdur. Primer PE’nin esas tedavisi farmakoterapi iken kazanılmış PE’de altta yatan sekonder nedenlerin tedavisi daha önemli olabilmek - tedir. Davranışsal tedaviler ilk aşamada kullanılmalı ve farmakolojik tedavilere eşlik etmelidir. Prematür ejakülasyon tedavisinde kullanı- labilecek farmakolojik ajanlar selektif serotonin geri alım inhibitörleri (SSRI), topikal anestezikler, tramadol, trisiklik antidepresanlar (TCA), fosfodiesteraz-5 inhibitörleri (PDE5i), α-1 blokerler ve bunlardan bazı- larının kombinasyonlarıdır. İnvaziv girişimler deneysel olup kılavuzlar tarafından önerilmemektedir. Tedavide hasta ve partner uyumu başarıyı getiren en önemli faktör olarak söylenebilir.
Anahtar Kelime: Current approach to premature ejaculation
Öz: Premature ejaculation (PE) is the most common ejaculation disorder affecting all age groups. It is a clinical condition that causes psychological stress and loss of self-confidence in the patient and has a negative effect on quality of life. While the main treatment of primary PE is pharmacotherapy, treatment of the underlying secondary causes may be more important in acquired PE. Behavioral treatments should be used in the initial phase and accompany pharmacological treatments. Pharmacological agents that can be used in the treatment of PE are selective serotonin reuptake inhibitors (SSRI), topical anesthetics, tramadol, tricyclic antidepressants (TCA), phosphodiesterase-5 inhibitors (PDE5i), α-1 blockers and some combinations of these. Invasive interventions are experimental and not recommended by the guidelines. Patient and partner compatibility can be said to be the most important factor that brings success in treatment.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007;51:816–23;discussion 824. [CrossRef]
- 2. Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, et al. Prevalence of the complaint of ejaculating prematurely and the four premature ejaculation syndromes: results from the Turkish Society of Andrology Sexual Health Survey. J Sex Med. 2011;8:540–8. [CrossRef]
- 3. Balci M, Aslan Y, Aydin AO, Kayali M, Tuncel A, Atan A. Türk erkeklerinde cinsel fonksiyon bozukluğu taraması: anket çalışması. Ortadoğu Tıp Derg. 2012;4:108–13.
- 4. Masters WH, Johnson VE, editors. Human sexual inadequacy. London; Boston: Churchill; Little, Brown; 1970. pp. 487
- 5. Serefoglu EC, McMahon CG, Walginger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the Second International Society for Sexual Medicine ad hoc committee for the definition of premature ejaculation. J Sex Med. 2014;11:1423–41. [CrossRef]
- 6. Waldinger MD, Schweitzer DH. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II –proposals for DSM-V and ICD-11. J Sex Med. 2006;3:693–705. [CrossRef]
- 7. World Health Organization. International Classification of Diseases - 11 for mortality and morbidity statistics 2020. Available at: https://icd.who.int/browse11/ Accessed: January 3, 2021.
- 8. Shindel AW, Althof SE, Carrier S, Chou R, McMahon CG, Mulhall JP, et al. Disorders of ejaculation: an AUA/SMSNA guideline. J Urol. 2022;207:504–12. [CrossRef]
- 9. Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A, et al. EAU Guidelines on sexual and reproductive health. EAU Guidelines 2022.
- 10. Gillman N, Gillman M. Premature ejaculation: aetiology and treatment strategies. Med Sci (Basel) 2019;7:102. [CrossRef]
- 11. Clement P, Giuliano F. Physiology and pharmacology of ejaculation. Basic Clin Pharmacol Toxicol. 2016;119 Suppl 3:18- 25. [CrossRef]
- 12. Raveendran AV, Agarwal A. Premature ejaculation –current concepts in the management: a narrative review. Int J Reprod Biomed. 2021;19:5–22. [CrossRef]
- 13. Giuliano F, Clement P. Pharmacology for the treatment of premature ejaculation. Pharmacol Rev. 2012;64:621–44. [CrossRef]
- 14. Yoshizumi M, Yonezawa A, Kimura Y, Watanabe C, Sakurada S, Mizoguchi H. Central mechanisms of apomorphine and m-chlorophenylpiperazine on synergistic action for ejaculation in rats. J Sex Med. 2021;18:231–9. [CrossRef]
- 15. Waldinger MD. The pathophysiology of lifelong premature ejaculation. Transl Androl Urol. 2016;5:424–33. [CrossRef]
- 16. Abu El-Hamd M, Saleh R, Majzoub A. Premature ejaculation: an update on definition and pathophysiology. Asian J Androl. 2019;21:425–32. [CrossRef]
- 17. Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, et al. Premature ejaculation: results from a five-country European observational study. Eur Urol. 2008;53:1048–57. [CrossRef]
- 18. Dinsmore WW, Ralph DJ, Kell P, Wylie KR, Dean JP, Novak C, et al. Evaluation of the Sexual Assessment Monitor, a diagnostic device used to electronically quantify ejaculatory latency time: findings from three studies. BJU Int. 2006;98:613–8. [CrossRef]
- 19. Rowland DL. A Conceptual approach to understanding and managing men’s orgasmic difficulties. Urol Clin North Am. 2021;48:577–90. [CrossRef]
- 20. Symonds T, Perelman MA, Althof S, Giuliano F, Martin M, May K. Development and validation of a premature ejaculation diagnostic tool. Eur Urol. 2007;52:565–73. [CrossRef]
- 21. Arafa M, Shamloul R. Development and evaluation of the Arabic Index of Premature Ejaculation (AIPE) J Sex Med. 2007;4:1750– 6. [CrossRef]
- 22. Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, et al. An update of the International Society of Sexual Medicine’s guidelines for the diagnosis and treatment of premature ejaculation (PE). Sex Med. 2014;2:60–90. [CrossRef]
- 23. Melnik T, Althof S, Atallah AN, Dos Santos Puga ME, Glina S, Riera R. Psychosocial interventions for premature ejaculation. Cochrane Database Syst Rev 2011;8:CD008195. [CrossRef]
- 24. Cormio L, Massenio P, La Rocca R, Verze P, Mirone V, Carrieri G. The combination of dapoxetine and behavioral treatment provides better results than dapoxetine alone in the management of patients with lifelong premature ejaculation. J Sex Med. 2015;12:1609–15. [CrossRef]
- 25. Pastore AL, Palleschi G, Leto A, Pacini L, Iori F, Leonardo C, Carbone A. A prospective randomized study to compare pelvic floor rehabilitation and dapoxetine for treatment of lifelong premature ejaculation. Int J Androl. 2012;35:528–33. [CrossRef]
- 26. Yildiz Y, Kilinc MF, Doluoglu OG. Is There Any Association Between Regular Physical Activity and Ejaculation Time? Urol J. 2018 Sep 26;15(5):285-289. [CrossRef]
- 27. Gul M, Bocu K, Serefoglu EC. Current and emerging treatment options for premature ejaculation. Nat Rev Urol. 2022;19:659–80. [CrossRef]
- 28. Chen T, Mulloy EA, Eisenberg ML. Medical treatment of disorders of ejaculation. Urol Clin North Am. 2022;49:219–30. [CrossRef]
- 29. European Medicines Agency. CHMP assessment report: lidocaine/ prilocaine plethora EMEA/H/C/002693/0000. European Medicines Agency; 2023.
- 30. European Medicines Agency. Fortacin: summary of product characteristics. EMEA/H/C/002693. Last updated on 20/09/2022.
- 31. Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo controlled study. BJU Int. 2004;93:1018–21. [CrossRef]
- 32. Liu H, Zhang M, Huang M, Cai H, Zhang Y, Liu G, Deng C. Comparative efficacy and safety of drug treatment for premature ejaculation: A systemic review and Bayesian network meta-analysis. Andrologia. 2020;52:e13806. [CrossRef]
- 33. Wyllie MG, Powell JA. The role of local anaesthetics in premature ejaculation. BJU Int. 2012;110:E943–8. [CrossRef]
- 34. Arafa M, Shamloul R. A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire. Ther Clin Risk Manag. 2007;3:527–31. https://www.dovepress. com/articles.php?article_id=1211
- 35. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res. 2004;16:369–81. [CrossRef]
- 36. Sathianathen NJ, Hwang EC, Mian R, Bodie JA, Soubra A, Lyon JA, et al. Selective serotonin re-uptake inhibitors for premature ejaculation in adult men. Cochrane Database Syst Rev. 2021;3:CD012799. [CrossRef]
- 37. McMahon CG. Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012;4:233–51. [CrossRef]
- 38. McMahon CG, Althof SE, Kaufman JM, Buvat J, Levine SB, Aquilina JA, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J Sex Med. 2011;8:524–39. [CrossRef]
- 39. McMahon CG, Lee SW, Kim SW, Moon DG, Kongkanand A, Tantiwongse K. The Asia-Pacific flexible dose study of dapoxetine and patient satisfaction in premature ejaculation therapy: the PASSION study. Sex Med. 2016;4:e18–27. [CrossRef]
- 40. Yue F-G, Dong L, Hu T-T, Qu X-Y. Efficacy of dapoxetine for the treatment of premature ejaculation: a meta-analysis of randomized clinical trials on intravaginal ejaculatory latency time, patient reported outcomes, and adverse events. Urology. 2015;85:856–61. [CrossRef]
- 41. Verze P, Cai T, Magno C, Sabella F, Cucchiara V, Palmieri A, Mirone V. Comparison of treatment emergent adverse events in men with premature ejaculation treated with dapoxetine and alternate oral treatments: results from a large multinational observational trial. J Sex Med. 2016;13:194–9. [CrossRef]
- 42. Balci M, Atan A, Senel C, Guzel O, Aslan Y, Lokman U, et al. Comparison of the treatment efficacies of paroxetine, fluoxetine and dapoxetine in low socioeconomic status patients with lifelong premature ejaculation. Cent European J Urol. 2019;72:185–90. [CrossRef]
- 43. Kowey PR, Mudumbi RV, Aquilina JW, DiBattiste PM. Cardiovascular safety profile of dapoxetine during the premarketing evaluation. Drugs R D. 2011;11:1–11. [CrossRef]
- 44. Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res. 2006;18:104–10. [CrossRef]
- 45. Abu El-Hamd M, Abdelhamed A. Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial. Andrologia. 2018;50. [CrossRef ]
- 46. Wu P-C, Hung C-S, Kang Y-N, Wu C-C. Tolerability and optimal therapeutic dosage of clomipramine for premature ejaculation: a systematic review and meta-analysis. Sex Med. 2021;9:100283. [CrossRef]
- 47. Bar-Or D, Salottolo KM, Orlando A, Winkler JV; Tramadol ODT Study Group. A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur Urol. 2012;61:736–43. [CrossRef]
- 48. Lu Y, Zhou Z, Zhang X, Cui Y, Zhang Y, Wang Y. The ınfluence of tramadol on ıntravaginal ejaculatory latency time and sexual satisfaction score in treating patients with premature ejaculation: a network meta-analysis. Am J Mens Health. 2021;15:15579883211057713. [CrossRef]
- 49. Simonsen U, Comerma-Steffensen S, Andersson KE. Modulation of dopaminergic pathways to treat erectile dysfunction. Basic Clin Pharmacol Toxicol. 2016;119 Suppl 3:63–74. [CrossRef]
- 50. McMahon CG, Stuckey BG. A, Andersen M, Purvis K, Koppiker N, Haughie S, Boolell M. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med. 2005;2:368–75. [CrossRef]
- 51. Abu El-Hamd M. Efficacy and safety of daily use of tadalafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial. Andrologia. 2018;50:e13005. [CrossRef]
- 52. Zhang X, Chi N, Sun M, Shan Z, Zhang Y, Cui Y. Phosphodiesterase-5 Inhibitors for premature ejaculation: systematic review and meta-analysis of placebo-controlled trials. Am J Mens Health. 2020;14:1557988320916406. [CrossRef]
- 53. Atan A, Basar MM, Tuncel A, Ferhat M, Agras K, Tekdogan U. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology. 2006;67:388–91. [CrossRef]
- 54. Dell’Atti L, Galosi AB, Ippolito C. A randomized single-center study to compare the efficacy and tolerability of tadalafil once daily plus lidocaine anesthetic spray on premature ejaculation. Eur Rev Med Pharmacol Sci. 2017;21:1036–40.
- 55. Sato Y, Tanda H, Nakajima H, Nitta T, Akagashi K, Hanzawa T, et al. Silodosin and its potential for treating premature ejaculation: a preliminary report. Int J Urol. 2012;19:268–72. [CrossRef]
- 56. McMahon C, Althof S, Rosen R, Giuliano F, Miner M, Osterloh IH, et al. PEPIX Multi-Centre Study Group. The oxytocin antagonist cligosiban prolongs ıntravaginal ejaculatory latency and ımproves patient-reported outcomes in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled proof-of concept trial (PEPIX). J Sex Med. 2019;16:1178–87. [CrossRef]
- 57. Althof S, Osterloh IH, Muirhead GJ, George K, Girard N; PEDRIX Multi-Centre Study Group. The oxytocin antagonist cligosiban fails to prolong ıntravaginal ejaculatory latency in men with lifelong premature ejaculation: results of a randomized, double-blind, placebo-controlled Phase IIb trial (PEDRIX). J Sex Med. 2019;16:1188–98. [CrossRef]
- 58. Tuken M, Kiremit MC, Serefoglu EC. On-demand modafinil improves ejaculation time and patient-reported outcomes in men with lifelong premature ejaculation. Urology. 2016;94:139–42. [CrossRef]
- 59. Alahwany A, Ragab MW, Zaghloul A, Abdallah H, Mostafa T. Hyaluronic acid injection in glans penis for treatment of premature ejaculation: a randomized controlled cross-over study. Int J Impot Res. 2019;31:348–55. [CrossRef]
- 60. Kosseifi F, Chebbi A, Raad N, Ndayra A, El Samad R, Achkar K, et al. Glans penis augmentation using hyaluronic acid for the treatment of premature ejaculation: a narrative review. Transl Androl Urol. 2020;9:2814–20. [CrossRef]
- 61. Califano G, Arcaniolo D, Ruvolo CC, Manfredi C, Smarrazzo F, Cilio S, Verze P. Glans penis augmentation: when, how, and why? Int J Impot Res. 2022;34:343–6. [CrossRef]
| APA | KÖSEOĞLU B, güzel ö, Atan A (2023). Prematür ejakülasyona güncel yaklaşım. , 103 - 111. 10.24898/tandro.2023.13334 |
| Chicago | KÖSEOĞLU BURAK,güzel özer,Atan Ali Prematür ejakülasyona güncel yaklaşım. (2023): 103 - 111. 10.24898/tandro.2023.13334 |
| MLA | KÖSEOĞLU BURAK,güzel özer,Atan Ali Prematür ejakülasyona güncel yaklaşım. , 2023, ss.103 - 111. 10.24898/tandro.2023.13334 |
| AMA | KÖSEOĞLU B,güzel ö,Atan A Prematür ejakülasyona güncel yaklaşım. . 2023; 103 - 111. 10.24898/tandro.2023.13334 |
| Vancouver | KÖSEOĞLU B,güzel ö,Atan A Prematür ejakülasyona güncel yaklaşım. . 2023; 103 - 111. 10.24898/tandro.2023.13334 |
| IEEE | KÖSEOĞLU B,güzel ö,Atan A "Prematür ejakülasyona güncel yaklaşım." , ss.103 - 111, 2023. 10.24898/tandro.2023.13334 |
| ISNAD | KÖSEOĞLU, BURAK vd. "Prematür ejakülasyona güncel yaklaşım". (2023), 103-111. https://doi.org/10.24898/tandro.2023.13334 |
| APA | KÖSEOĞLU B, güzel ö, Atan A (2023). Prematür ejakülasyona güncel yaklaşım. Androloji Bülteni, 25(2), 103 - 111. 10.24898/tandro.2023.13334 |
| Chicago | KÖSEOĞLU BURAK,güzel özer,Atan Ali Prematür ejakülasyona güncel yaklaşım. Androloji Bülteni 25, no.2 (2023): 103 - 111. 10.24898/tandro.2023.13334 |
| MLA | KÖSEOĞLU BURAK,güzel özer,Atan Ali Prematür ejakülasyona güncel yaklaşım. Androloji Bülteni, vol.25, no.2, 2023, ss.103 - 111. 10.24898/tandro.2023.13334 |
| AMA | KÖSEOĞLU B,güzel ö,Atan A Prematür ejakülasyona güncel yaklaşım. Androloji Bülteni. 2023; 25(2): 103 - 111. 10.24898/tandro.2023.13334 |
| Vancouver | KÖSEOĞLU B,güzel ö,Atan A Prematür ejakülasyona güncel yaklaşım. Androloji Bülteni. 2023; 25(2): 103 - 111. 10.24898/tandro.2023.13334 |
| IEEE | KÖSEOĞLU B,güzel ö,Atan A "Prematür ejakülasyona güncel yaklaşım." Androloji Bülteni, 25, ss.103 - 111, 2023. 10.24898/tandro.2023.13334 |
| ISNAD | KÖSEOĞLU, BURAK vd. "Prematür ejakülasyona güncel yaklaşım". Androloji Bülteni 25/2 (2023), 103-111. https://doi.org/10.24898/tandro.2023.13334 |
